Opendata, web and dolomites

Oralis SIGNED

Oralis, The first oral human insulin treatment for Type 2 Diabetes Mellitus

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Oralis project word cloud

Explore the words cloud of the Oralis project. It provides you a very rough idea of what is the project "Oralis" about.

social    region    adherence    patients    considerable    share    5000    morbidities    thousands    opens    bgl    last    sme    pain    estimation    orally    claim    life    gastrointestinal    global    bioavailable    hundreds    est    liver    49    solution    globally    bn    harsh    injectable    overcome    415m    instrument    creation    insulin    61    t2dm    oralis    prevention    quality    huge    burden    pharmaceuticals    longer    confirm    tract    efficacy    concentration    billion    market    demonstrated    transform    individuals    oral    mellitus    lifespans    trial    caring    capability    300    commercial    commercialise    lives    protein    oramed    finalise    sufficient    levels    paradigm    gt    treatment    pod    glucose    blood    revenue    prognosis    diabetes    trials    newest    trade    daily    protects    disease    injected    eventual    patient    generate    49m    649    doses    options    annually    2020    people    agreements    multiple    worth    injections    first    therapies    181m    type    proven    clinical    glycaemic    injecting    created    century    stigma    co   

Project "Oralis" data sheet

The following table provides information about the project.

Coordinator
ORAMED LTD 

Organization address
address: ELZA ST 2
city: JERUSALEM
postcode: 9370648
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-12-01   to  2020-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ORAMED LTD IL (JERUSALEM) coordinator 50˙000.00

Map

 Project objective

Type 2 Diabetes Mellitus (T2DM) affects 415M people globally, 49M of them within Europe. Caring for these individuals costs Europe €181M billion annually. However, more needs to be done as T2DM and its related co-morbidities claim hundreds of thousands of lives each year in the region. The early control of blood glucose levels (BGL) is the key to the prevention of the disease, and longer lifespans with better prognosis and higher quality of life for T2DM patients. The last century has seen considerable development in T2DM treatment, but the eventual solution to control BGL for many patients are multiple daily insulin injections. This has created a huge global market to be worth €49 billion (est. 2020). The pain, social stigma, and burden associated with injecting insulin contribute to a non-adherence to treatment that has been estimated to be as high as 61%, at a cost 9,649€ per patient per year. Oramed Pharmaceuticals (Oramed) will transform this paradigm with its POD™ technology. It protects protein therapies like insulin from the harsh conditions in the gastrointestinal tract, allowing then to be taken orally. This opens a way into oral insulin treatment to overcome many of the issues contributing to non-adherence of injected insulin treatment in T2DM patients. Using POD™ technology Oramed has produced the first oral insulin and demonstrated its efficacy in Phase II clinical trials with >300 patients and >5000 doses. We have proven oralis capability to deliver to the liver bioavailable insulin at sufficient concentration to produce significant glucose control in all glycaemic parameters in T2DM patients. Through the SME instrument Oramed will finalise the Phase III clinical trial to confirm the efficacy of oralis for glycaemic control in T2DM patients. We have already reach commercial agreements to commercialise oralis. Our estimation is to generate a similar revenue creation and market share as the newest injectable insulin options of €1.7 bn in 5 years.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ORALIS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ORALIS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DetectInMen (2019)

Infection detection in human semen

Read More  

COPI (2020)

Carbon Offset Plug-in

Read More  

ADAPTOS (2019)

ADAPTOS - Changing the way bone voids are treated

Read More